Literature DB >> 227981

Cyclic adenosine monophosphate response to prostaglandin E2 on subpopulations of human lymphocytes.

J S Goodwin, P A Kaszubowski, R C Williams.   

Abstract

Receptors for prostaglandin E2 or histamine were measured on subpopulations of human lymphocytes, using the cyclic AMP increase after exposure to prostaglandin or histamine as an indicator for the presence of receptors. The cyclic AMP response to prostaglandin E2 was similar in unfractionated lymphocytes and the T-enriched and T-depleted fractions. Within the T-enriched population, T cells bearing a receptor for the Fc portion of IgG (T gamma-cells) had a 27.4-fold rise in cyclic AMP after exposure to prostaglandin E2, whereas the remaining T cells (non-T gamma cells) had a fourfold increase. It would appear that prostaglandin receptors are concentrated on a small subfraction of T gamma cells, comprising approximately 15% of the T-cell population. The cyclic AMP response to histamine was less than twofold in all lymphocyte fractions.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 227981      PMCID: PMC2185694          DOI: 10.1084/jem.150.5.1260

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  13 in total

1.  High-affinity binding sites for prostaglandin E on human lymphocytes.

Authors:  J S Goodwin; A Wiik; M Lewis; A D Bankhurst; R C Williams
Journal:  Cell Immunol       Date:  1979-03-01       Impact factor: 4.868

2.  Subpopulations of human T lymphocytes. II. Effect of thymopoietin, corticosteroids, and irradiation.

Authors:  S Gupta; R A Good
Journal:  Cell Immunol       Date:  1977-11       Impact factor: 4.868

3.  Mitogen-induced changes in lymphocyte prostaglandin levels: a signal for the induction of suppressor cell activity.

Authors:  D R Webb; I Nowowiejski
Journal:  Cell Immunol       Date:  1978-11       Impact factor: 4.868

4.  Sensitivity of lymphocytes to prostaglandin E2 increases in subjects over age 70.

Authors:  J S Goodwin; R P Messner
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

5.  Partial reversal of the cellular immune defect in common variable immunodeficiency with indomethacin.

Authors:  J S Goodwin; A D Bankhurst; S A Murphy; D S Selinger; R P Messner; R C Williams
Journal:  J Clin Lab Immunol       Date:  1978-11

6.  Idiotype suppression. II. Amplification of a suppressor T cell with anti-idiotypic activity.

Authors:  K Eichmann
Journal:  Eur J Immunol       Date:  1975-08       Impact factor: 5.532

7.  Enhancement of lymphocyte blastogenic and delayed hypersensitivity skin responses by indomethacin.

Authors:  C C Muscoplat; P M Rakich; C O Thoen; D W Johnson
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

8.  Generation of suppressor lymphocytes during sensitization in culture against a syngeneic tumor: affinity chromatography on insolubilized histamine.

Authors:  B Schechter; S Segal; M Feldman
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

9.  Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. Changes with mitogen dose and preincubation.

Authors:  J S Goodwin; R P Messner; G T Peake
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

10.  Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell.

Authors:  J S Goodwin; A D Bankhurst; R P Messner
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

View more
  13 in total

Review 1.  The role of prostaglandins in altered leukocyte function in multiple sclerosis.

Authors:  P Dore-Duffy; S Y Ho; M Longo
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Differential sensitivity to cAMP among human cord and maternal/adult peripheral lymphocytes discloses differences between PHA- and OKT3-induced activation pathways.

Authors:  N Papadogiannakis; S A Johnsen; S Rosberg; R G Andersson; L B Olding
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

3.  Different effect of prostaglandin E2 on B-cell activation by two distinct B-cell differentiation factors, B151-TRF1/IL-5 and B151-TRF2: selective inhibition of B151-TRF2-induced antibody response through increases in intracellular cyclic AMP levels.

Authors:  K Ishihara; S Ono; Y Takahama; F Hirayama; H Hirano; K Itoh; K Dobashi; S Murakami; Y Katoh; M Yamaguchi
Journal:  Immunology       Date:  1989-10       Impact factor: 7.397

Review 4.  Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy.

Authors:  P Uotila
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

5.  The role of TG lymphocytes in cell-mediated immunity in patients with periodontal disease.

Authors:  L Ivanyi; B Topic; P M Lydyard
Journal:  Clin Exp Immunol       Date:  1981-12       Impact factor: 4.330

6.  Inhibition of anti-CD3 monoclonal antibody-induced T-cell proliferation by dexamethasone, isoproterenol, or prostaglandin E2 either alone or in combination.

Authors:  L Elliott; W Brooks; T Roszman
Journal:  Cell Mol Neurobiol       Date:  1992-10       Impact factor: 5.046

Review 7.  Regulation of the immune response by prostaglandins.

Authors:  J S Goodwin; J Ceuppens
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

8.  Inhibition of lymphocyte response by prostaglandin-producing suppressor cells in patients with melanoma.

Authors:  J L Murray; G M Kollmorgen
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

9.  Selective inhibition of thromboxane biosynthesis in human blood mononuclear cells and the effects of mitogen-stimulated lymphocyte proliferation.

Authors:  D Gordon; A M Nouri; R U Thomas
Journal:  Br J Pharmacol       Date:  1981-10       Impact factor: 8.739

Review 10.  Lithium and hematopoiesis.

Authors:  R D Barr; P R Galbraith
Journal:  Can Med Assoc J       Date:  1983-01-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.